ArticleInternational urology and nephrology2026
Interstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiovascular Complications Associated with Uro-Oncology Treatments-A Primer for the Clinician.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study aims to detect potential signals of interstitial lung disease (ILD) associated with antiandrogen agents by employing a multi-algorithm, dual-level (Standardized MedDRA Query [SMQ] and Preferred Term [PT]) framework combined with the updated FDA Adverse Event Reporting System (FAERS) dataset (through 2024).
methodsWe analyzed data from the fourth quarter of 2003 through the fourth quarter of 2024. Disproportionality analysis employed four complementary methods: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM). Signals were evaluated at both the SMQ and PT levels.
resultsA total of 761 cases of ILD associated with antiandrogen agents were analyzed. We identified seven agents showing positive ILD signals in FAERS. They were apalutamide, bicalutamide, degarelix, darolutamide, flutamide, goserelin, and nilutamide. Among them, darolutamide stood out with a newly identified pharmacovigilance signal, whereas no such signal had been detected in prior FAERS analyses. Bicalutamide exhibited positive signals for both "Interstitial lung disease" and "Pulmonary fibrosis" at the PT level, a pattern not seen with the other drugs. Japan contributed the most reports (61.37%); death and hospitalization were the most common outcomes (54.80%). Female-related ILD reports were mainly observed with goserelin and leuprolide used for breast cancer.
conclusionThis study identified seven antiandrogens with pharmacovigilance signals, among which the signal for darolutamide was detected for the first time. The dual-level analysis generated the hypothesis that bicalutamide-associated ILD may have a greater tendency to evolve into a fibrotic phenotype. The observed Japanese predominance in reporting likely reflects regulatory and reporting-related factors rather than a true biologic excess risk. Female-related ILD reports represent solely a signal-generating observation. These findings are exploratory and require further validation.
Indexed as
Identifiers
42154420What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.